TScan Therapeutics Director Buys $26,450 in Company Shares by Investing.com

Director of TScan Therapeutics, Inc. (NASDAQ:TCRX) Barbara Klencke recently increased her stake in the company, acquiring shares valued at a total of $26,450. The transaction, which took place on September 23, involved the purchase of 5,000 shares of TScan’s voting common stock at a price of $5.29 per share.

This purchase brings Klencke’s direct ownership of TScan Therapeutics to 45,000 shares. In addition, it is worth noting that Klencke is associated with the Klencke Huestis Trust, which owns 25,000 shares of the company. According to a footnote in the filing, Klencke serves as a co-trustee with her husband for the trust and disclaims beneficial ownership of those securities except for her pecuniary interest.

TScan Therapeutics, headquartered in Waltham, Massachusetts, operates in the biotechnology sector, focusing on the development of biologics. The latest insider trade provides an update on the company’s stock moves by its executives, which is often of interest to investors tracking ownership trends and sentiment within the company.

The reported trades were filed with the Securities and Exchange Commission and were publicly disclosed on September 24, following standard regulatory requirements for insider trading. The signature of Barbara Klencke was affixed to the document, confirming the accuracy and completeness of the data reported.

InvestingPro Insights

TScan Therapeutics, Inc. (NASDAQ:TCRX) has seen significant insider activity recently, with director Barbara Klencke increasing her stake in the company. As investors assess the confidence that insiders have in their company, it is critical to consider the company’s financial health and market position. TScan Therapeutics currently has a market capitalization of approximately $271.23 million, according to InvestingPro data. Despite challenging market conditions, TScan shares have shown resilience over the past year with a return of 96.23%, although recent trends point to a decline of 10.81% year-to-date through 2024.

InvestingPro Tips suggests keeping TScan’s valuation metrics in mind. The company’s price-to-earnings (P/E) ratio is -2.61, reflecting current earnings challenges. Additionally, the price-to-book (P/B) ratio for the trailing twelve months ending Q2 2024 is 1.06, which may indicate that the stock is reasonably valued relative to its assets and liabilities.

Investors should also note that TScan’s revenue has fallen 25.65% over the past twelve months through Q2 2024, a significant consideration for those looking at the company’s growth trajectory. Furthermore, the gross profit margin was reported at -694.11%, a figure that highlights the company’s current difficulties in generating profit from revenues. These financial metrics are essential for investors to evaluate the company’s performance and future potential.

For those seeking a more comprehensive analysis, InvestingPro offers additional advice on TScan Therapeutics. In fact, there are 12 more InvestingPro tips available that can give investors a deeper understanding of a company’s financial health and stock performance.

This article was generated with support from AI and reviewed by an editor. For more information, see T&C.